◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › R › RGC

Regencell Bioscience Holdings Ltd (RGC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-08-30

Regencell Bioscience Holdings Ltd (RGC) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Causeway Bay, Hong Kong with about 10 employees. Its market capitalization is roughly $3 billion.

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

Interactive charts & full statements →

RGC Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Total Revenue——$0M$0M$0M$0M$0M$0M$3.2B$3.2B$3.1B$3.0B$3.0B$2.8B$2.7B$2.8B$2.9B$2.8B$2.7B$2.6B$2.5B
Gross Profit—$0M($1M)($1M)($1M)$0M$0M—$3.0B$2.0B$1.9B$2.9B$2.9B$2.7B$2.6B$2.7B$1.7B$2.7B$2.6B$2.5B$2.4B
Gross Margin %————————96.1%61.6%61.4%96.3%96.4%96.4%96.4%96.4%60.0%96.2%96.1%96.0%96.2%
Operating Income (EBIT)($7M)($4M)($5M)($6M)($8M)($1M)($1M)$0M$272M$344M$339M$306M$340M$334M$221M$216M$313M$284M$322M$308M$269M
Operating Margin %————————8.6%10.8%10.8%10.2%11.2%11.8%8.2%7.7%10.8%10.2%12.1%11.9%10.7%
Net Income($7M)($4M)($4M)($6M)($7M)($1M)($1M)$0M$112M$170M$153M$106M$158M$145M$40M$78M$96M$72M$363M$86M$91M
Net Margin %————————3.5%5.3%4.9%3.5%5.2%5.1%1.5%2.8%3.3%2.6%13.6%3.3%3.6%
EBITDA($7M)($3M)($4M)($5M)($7M)($1M)($1M)$0M$469M$512M$470M$391M$469M$422M$260M$352M$512M$200M$676M$215M$233M
Earnings Per Share (EPS)$-0.01$-0.01$-0.01$-0.01$-0.02$-0.00$-0.00$-0.00$0.02$0.03$0.03$0.02$0.03$0.02$0.26$0.01$0.02$1.63$1.66$1.73$0.59
Shares Outstanding (M)494M494M494M494M494M480M480M480M5,965M5,958M5,947M5,940M5,917M——5,872M—44M219M50M154M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-09-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30
Total Revenue————————
Gross Profit$0M——————($1M)
Operating Income (EBIT)($5M)($2M)($2M)($1M)$0M$0M$0M$0M
Net Income($5M)($2M)($2M)($1M)$0M$0M$0M$0M
EBITDA($5M)($2M)($2M)($1M)$0M$0M($1M)($1M)
Earnings Per Share (EPS)$-0.01$-0.00$-0.00$-0.00$-0.00$-0.00$-0.00—
Shares Outstanding (M)494M494M494M494M494M494M494M—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGC Free Cash Flow History

Cash flowTTM → 2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Cash from Operations (CFO)—($3M)($4M)($5M)($5M)($1M)($1M)$0M$410M$410M$434M$349M$347M$347M$353M$259M$411M$270M$800M$304M$386M
Capital Expenditures (CapEx)$0M$0M$0M$0M$1M$0M$0M$0M$250M$215M$186M$157M$112M$89M$87M$98M$109M$0M$0M$0M$0M
Free Cash Flow (FCF)—($3M)($4M)($5M)($6M)($1M)($1M)($1M)$160M$196M$249M$192M$235M$257M$266M$161M$302M$270M$800M$304M$386M
FCF Margin %————————5.0%6.1%8.0%6.4%7.7%9.1%9.9%5.7%10.4%9.7%30.1%11.7%15.3%
Dividends Paid————————$139M$139M$139M$295M$132M$287M$130M$327M$111M—$485M$179M$175M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-03-312024-06-302023-12-312023-09-30
Cash from Operations (CFO)($3M)($2M)($2M)$2M
Capital Expenditures (CapEx)$0M$0M$0M$0M
Free Cash Flow (FCF)($3M)($2M)($2M)$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RGC Balance Sheet History

Balance sheet2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Total Assets$3M$6M$8M$13M$18M$0M$1M$0M$2.8B$2.6B$2.6B$2.5B$2.7B$2.2B$2.3B$2.5B$2.6B$2.6B$2.6B$2.5B$2.5B
Cash & Cash Equivalents$2M$2M$3M$2M$6M$0M$0M$0M$229M$246M$220M$147M$281M$110M$253M$205M$328M$170M$435M$162M$196M
Total Liabilities$2M$1M$0M$1M$1M$4M$3M$2M$3.7B$3.5B$3.5B$3.4B$3.4B$2.9B$2.9B$3.0B$2.9B$2.8B$2.8B$2.5B$2.5B
Total Debt (Short + Long-Term)$0M$0M$0M$0M$0M$4M$3M$2M$27M$26M$27M$27M$30M$22M$21M$96M$17M$77M$0M$52M$68M
Total Shareholders' Equity$1M$5M$8M$12M$17M($4M)($3M)($2M)($856M)($839M)($878M)($895M)($713M)($697M)($571M)($490M)($247M)($242M)($119M)($21M)$31M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RGC viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

← RGASAll “R” companiesRGCO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.